Effect of sunitinib on platelet function
Protocolnummer:
16-4-270
Ziekenhuizen:
Maastricht UMC+
Titel:
Effect of sunitinib on platelet function
To investigate whether platelet count and activation can be used to monitor sunitinib pharmacodynamics and response to therapy.
Behandeling:
Sunitinib. To investigate whether platelet count and activation can be used to monitor sunitinib pharmacodynamics and response to therapy.
Stadium:
Belangrijkste in/exclusiecriteria:
- Inclusie criteria:
- Patients (men or women) with histologically proven renal cell cancer who are starting treatment with sunitinib
- > 18 years
- Hb >5.6 mmol/L
- Exclusie criteria:
- Patients with known genetic abnormalities affecting platelet function and coagulation
- Patients who received anti-platelet medication during the study or 14 days before the onset of the study
- Patients who have received blood or platelet transfusion during the study or 14 days before the onset of the study
- Patients who have a diagnosed active infection, ulcers and/or non-healing wounds.
- Patients who are pregnant or breastfeeding
- Active thrombosis
Contactpersoon:
Marijke J.E. Kuijpers, PhD: Marijke.Kuijpers@maastrichtuniversity.nl
Maureen J. Aarts, MD, PhD: mjb.essers.aarts@mumc.nl